Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice

@article{Greenough2005DevelopmentAC,
  title={Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice},
  author={Thomas C. Greenough and Gregory J Babcock and Anjeanette Roberts and Hector J. Hernandez and William D. Thomas and Jennifer A. Coccia and Robert F. Graziano and Mohan Srinivasan and Israel Lowy and Robert W. Finberg and Kanta Subbarao and Leatrice N. Vogel and Mohan Somasundaran and Katherine Luzuriaga and John L. Sullivan and Donna M. Ambrosino},
  journal={The Journal of Infectious Diseases},
  year={2005},
  volume={191},
  pages={507 - 514}
}
Abstract Background. Severe acute respiratory syndrome (SARS) remains a significant public health concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARSCoV) could provide protection for exposed individuals. Methods. Transgenic mice with human immunoglobulin genes were immunized with the recombinant major surface (S) glycoprotein ectodomain of SARS-CoV. Epitopes of 2 neutralizing MAbs derived from these mice were mapped and… 

Figures from this paper

Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

TLDR
It is concluded that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants is identified.

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

TLDR
Results suggest that a cocktail of hmAbs that can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS‐CoV infection, and indicate that a similar approach may be applied to treat other viral infections.

Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model

TLDR
5H10, which recognized the same epitope that is also a cleavage site critical for the entry of SARS-CoV into host cells, inhibited propagation of the virus and pathological changes found in Rhesus macaques infected with the virus through the nasal route.

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

TLDR
It is shown here that anti-SARS-CoV antibodies do not convert the abortive infection of primary human macrophages by SARS- coV into a productive one.

Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness

TLDR
Broadly neutralizing antibodies that prevent infection of related viruses represent an important immunostrategy for combating coronavirus infections; however, for this strategy to succeed, it is essential to uncover nAb-mediated escape pathways and to pioneer strategies that prevent escape.

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

TLDR
Two human monoclonal antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

TLDR
The authors' data show that the neutralizing mAbs bind to the angiotensin-converting enzyme 2 (ACE2) receptor-binding domain (RBD) of the SARS S protein, and that the dominance of a 33 amino acid residue loop of theSARS-CoV RBD is independent of repertoire, species, quaternary structure, and importantly, the technology used to derive the mAbs.

Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters

TLDR
The demonstration of successful postexposure M Ab 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.

Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain

TLDR
This study characterized the neutralization and viral entry determinants within the ACE2-binding domain of the S glycoprotein and found that these basic residues are essential for immunogenicity of the major neutralizing domain and for viral entry.
...

References

SHOWING 1-10 OF 26 REFERENCES

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.

  • J. SuiWenhui Li W. Marasco
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2004
TLDR
Data suggest that the 80R human monoclonal antibody may be a useful viral entry inhibitor for the emergency prophylaxis and treatment of SARS, and that the ACE2-binding site of S1 could be an attractive target for subunit vaccine and drug development.

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.

  • H. BishtA. Roberts B. Moss
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2004
TLDR
Intranasal or intramuscular inoculations of BALB/c mice with MVA/S produced serum antibodies that recognized the SARS S in ELISA and neutralized SARS-CoV in vitro, demonstrating a role for antibody to S in protection.

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

TLDR
Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model, and induces T cell and neutralizing antibody responses, as well as protective immunity, in a mouse model.

Amino Acids 270 to 510 of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Are Required for Interaction with Receptor

TLDR
The construction and expression of a soluble codon-optimized SARS-CoV S glycoprotein comprising the first 1,190 amino acids of the native S glyCoprotein (S1190) is described, indicating that synthetic S Glycoprotein is modified correctly in a mammalian expression system.

A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2*

TLDR
It is demonstrated that a 193-amino acid fragment of the S protein bound ACE2 more efficiently than did the full S1 domain (residues 12–672) and a point mutation at aspartic acid 454 abolished association of the fullS1 domain and of the 193-residue fragment with ACE2.

Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229E

TLDR
The data suggest that the domain of the spike protein between amino acids 417 and 547 is required for the binding of HCoV-229E to its hAPN receptor.

A novel coronavirus associated with severe acute respiratory syndrome.

TLDR
A novel coronavirus is associated with this outbreak of severe acute respiratory syndrome, and the evidence indicates that this virus has an etiologic role in SARS.

The Spike but Not the Hemagglutinin/Esterase Protein of Bovine Coronavirus Is Necessary and Sufficient for Viral Infection

TLDR
It is demonstrated that the S protein but not the HE protein of BCV is necessary and sufficient for infection of the chimeric viruses in HRT-18 cells, suggesting that BCV likely uses the Sprotein as a primary vehicle to infect permissive cells.

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

TLDR
It is found that a soluble form of ACE2, but not of the related enzyme ACE1, blocked association of the S1 domain with Vero E6 cells, indicating that ACE2 is a functional receptor for SARS-CoV.